Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2024-10-01 Epub Date: 2024-07-08 DOI:10.1097/MEG.0000000000002816
Sara Kolehmainen, Jaakko Rautakorpi, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Kimmo Salminen, Taina Sipponen
{"title":"Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.","authors":"Sara Kolehmainen, Jaakko Rautakorpi, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Kimmo Salminen, Taina Sipponen","doi":"10.1097/MEG.0000000000002816","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A few prospective cohort studies support the safety of switching from intravenous to subcutaneous administration of vedolizumab during maintenance therapy in patients with inflammatory bowel disease. Real-life data on switching after intravenous induction therapy are lacking.</p><p><strong>Objective: </strong>The aim was to obtain real-world data on subcutaneous vedolizumab treatment in patients with inflammatory bowel disease after switching from intravenous vedolizumab induction or maintenance therapy, and to evaluate treatment persistence, safety, and changes in disease activity and serum vedolizumab concentrations.</p><p><strong>Methods: </strong>We performed a retrospective registry-based study of inflammatory bowel disease patients who received subcutaneous vedolizumab therapy in two tertiary centres.</p><p><strong>Results: </strong>Altogether, 103 patients (26 Crohn's disease and 77 ulcerative colitis) switching from intravenous maintenance therapy (group 1) and 44 patients (14 and 30, respectively) switching from intravenous induction therapy (group 2) were included. At 6 months from baseline, 90.3% of the patients in group 1 and 90.9% of the patients in group 2 continued on subcutaneous vedolizumab. After the switch in group 1, disease activity remained stable. In group 2, clinical disease activity decreased significantly in ulcerative colitis patients ( P  = 0.002). The median serum vedolizumab concentration was 34.00 µg/ml during subcutaneous maintenance therapy in group 1, which was significantly higher than the median concentration during intravenous therapy (17.00 µg/ml, P  < 0.001), but remained unchanged in group 2 after the switch (31.50 µg/ml).</p><p><strong>Conclusion: </strong>Based on these data, subcutaneous vedolizumab treatment is well-tolerated and the treatment persistence remains high after switching from intravenous to subcutaneous vedolizumab therapy.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000002816","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A few prospective cohort studies support the safety of switching from intravenous to subcutaneous administration of vedolizumab during maintenance therapy in patients with inflammatory bowel disease. Real-life data on switching after intravenous induction therapy are lacking.

Objective: The aim was to obtain real-world data on subcutaneous vedolizumab treatment in patients with inflammatory bowel disease after switching from intravenous vedolizumab induction or maintenance therapy, and to evaluate treatment persistence, safety, and changes in disease activity and serum vedolizumab concentrations.

Methods: We performed a retrospective registry-based study of inflammatory bowel disease patients who received subcutaneous vedolizumab therapy in two tertiary centres.

Results: Altogether, 103 patients (26 Crohn's disease and 77 ulcerative colitis) switching from intravenous maintenance therapy (group 1) and 44 patients (14 and 30, respectively) switching from intravenous induction therapy (group 2) were included. At 6 months from baseline, 90.3% of the patients in group 1 and 90.9% of the patients in group 2 continued on subcutaneous vedolizumab. After the switch in group 1, disease activity remained stable. In group 2, clinical disease activity decreased significantly in ulcerative colitis patients ( P  = 0.002). The median serum vedolizumab concentration was 34.00 µg/ml during subcutaneous maintenance therapy in group 1, which was significantly higher than the median concentration during intravenous therapy (17.00 µg/ml, P  < 0.001), but remained unchanged in group 2 after the switch (31.50 µg/ml).

Conclusion: Based on these data, subcutaneous vedolizumab treatment is well-tolerated and the treatment persistence remains high after switching from intravenous to subcutaneous vedolizumab therapy.

炎症性肠病患者从静脉注射维多珠单抗转为皮下注射维多珠单抗维持治疗的实际经验。
背景:一些前瞻性队列研究支持炎症性肠病患者在维持治疗期间将静脉注射维多珠单抗转换为皮下注射的安全性。目前尚缺乏静脉诱导治疗后改用皮下注射的真实数据:目的:获取炎症性肠病患者从静脉注射维多珠单抗诱导或维持治疗转为皮下注射维多珠单抗治疗的真实数据,并评估治疗的持续性、安全性以及疾病活动性和血清维多珠单抗浓度的变化:我们对两个三级中心接受皮下注射维多珠单抗治疗的炎症性肠病患者进行了一项基于登记的回顾性研究:共有103名患者(26名克罗恩病患者和77名溃疡性结肠炎患者)从静脉维持治疗(第1组)转为皮下注射维多珠单抗治疗,44名患者(分别为14名和30名)从静脉诱导治疗(第2组)转为皮下注射维多珠单抗治疗。自基线起 6 个月后,90.3% 的第 1 组患者和 90.9% 的第 2 组患者继续使用皮下注射维多珠单抗。第 1 组患者换药后,疾病活动保持稳定。在第 2 组中,溃疡性结肠炎患者的临床疾病活动明显减少(P = 0.002)。第 1 组患者在皮下注射维持治疗期间,血清中位维度利珠单抗浓度为 34.00 µg/ml,明显高于静脉注射治疗期间的中位浓度(17.00 µg/ml,P=0.002):根据这些数据,皮下注射维多珠单抗治疗耐受性良好,从静脉注射转为皮下注射维多珠单抗治疗后,治疗持续率仍然很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信